We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. CSF-1 low-dose pilocarpine drops improve reading vision ...
Please provide your email address to receive an email when new articles are posted on . INDIANAPOLIS — Individuals with mild to moderate presbyopia who were treated with CSF-1 were able to achieve and ...
SAN DIEGO -- A low-dose formulation of pilocarpine significantly improved visual acuity in presbyopia without adversely affecting distance vision, results of two randomized trials showed. As compared ...
On February 26, 2024, the National Institute of Standards and Technology (NIST) released the Cybersecurity Framework version 2.0 (CSF 2.0). CSF 2.0 is a generational update to NIST’s foundational ...
SAN FRANCISCO, Nov. 18, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced its oral presentation highlighting preclinical data on NKTR-422 at the 2024 American College of ...
The phase 3 NEAR-1 and NEAR-2 trials included 613 patients aged 45 to 64 years with presbyopia. Positive results were announced from two phase 3 trials evaluating the efficacy and safety of CSF-1, a ...
On February 26, 2024, the National Institute of Standards and Technology (NIST) released the long-awaited second version of the Cybersecurity Framework (CSF). Dubbed “CSF 2.0,” it contains a few ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results